GB1569034A - Creation of Inventions and Patents with Artificial Intelligence

GB1569034A – 1,4-dioxido-3-methyl-quinoxaline (2) carboxamides
– Google Patents

GB1569034A – 1,4-dioxido-3-methyl-quinoxaline (2) carboxamides
– Google Patents
1,4-dioxido-3-methyl-quinoxaline (2) carboxamides

Download PDF
Info

Publication number
GB1569034A

GB1569034A
GB2356/77A
GB235677A
GB1569034A
GB 1569034 A
GB1569034 A
GB 1569034A
GB 2356/77 A
GB2356/77 A
GB 2356/77A
GB 235677 A
GB235677 A
GB 235677A
GB 1569034 A
GB1569034 A
GB 1569034A
Authority
GB
United Kingdom
Prior art keywords
formula
compound
quinoxaline
dioxido
methyl
Prior art date
1976-01-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired

Application number
GB2356/77A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1976-01-20
Filing date
1977-01-20
Publication date
1980-06-11

1976-01-20
Priority claimed from CH63476A
external-priority
patent/CH627174A5/en

1977-01-20
Application filed by Ciba Geigy AG
filed
Critical
Ciba Geigy AG

1980-06-11
Publication of GB1569034A
publication
Critical
patent/GB1569034A/en

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings

C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems

C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms

C07D241/52—Oxygen atoms

A—HUMAN NECESSITIES

A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES

A23K—FODDER

A23K20/00—Accessory food factors for animal feeding-stuffs

A23K20/10—Organic substances

A23K20/116—Heterocyclic compounds

A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P3/00—Drugs for disorders of the metabolism

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P31/04—Antibacterial agents

Description

PATENT SPECIFICATION ( 11) 1569034
( 21) Application No 2356/77 ( 22) Filed 20 Jan 1977 he ( 31) Convention Application No634/76 ( 19) ( 32) Filed 20 Jan 1976 ( 31) Convention Application No 14920/76 ( 32) Filed 26 Nov 1976 in ( 33) Switzerland (CH) ( 44) Complete Specification published 11 June 1980 ( 51) INT CL 3 C 07 D 241/52; A 61 K 31/495 ( 52) Index at acceptance C 2 C 1628 200 20 Y 247 250 252 25 Y 280 305 30 Y 326 334 342 34 Y 351 355 581 584 625 62 X 801 802 80 Y AA KS KV ( 54) 1,4-DIOXIDO-3-METHYL-QUINOXALINE ( 2) CARBOXAMIDES ( 71) We, CIBA-GEIGY AG, a body corporate organised according to the laws of Switzerland, of Basle, Switzerland, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to
be performed, to be particularly described in and by the following statement:
The present invention relates to quinoxaline-di-n-oxide derivatives, a process 5 for their manufacture, compositions which contain these derivatives as active component, a method of controlling pathogenic microorganisms which comprises the use of the compounds, and to the use thereof as feed additives for stimulating the growth of domestic animals and productive livestock.
The quinoxaline-di-N-oxide derivatives of the invention have the general 10 formula I 0 1 R CO -N/ c Cla Co A-CN (I) N CH 3 0 wherein R represents a hydrogen atom, an alkyl group of 1 to 12 carbon atoms, a cyanoalkyl group containing 1 to 4 carbon atoms in the alkyl portion thereof or 15 an allyl group, and A represents a straight-chain or branched alkylene bridge member containing 1 to 4 carbon atoms.
By alkyl groups are meant the following groups: methyl, ethyl, the isomers of the propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl and dodecyl 20 group.
The compounds of the formula I can be obtained by methods which are known per se (cf DOS 1,670,935).
The reaction can be illustrated by the following formulae:
R \l NO + CH 3 CO-CH 2 CO N-A-CN base (amine) 25 (II)0 (III) 1 r Av Q 04 2 0 R.
CO -N WIX i A-CN (I) N CH 3 The reaction is carried out in an organic solvent which is inert to the reactants, such as an alcohol, acetonitrile, dimethyl formamide, tetrahydrofurane, dioxane, benzene, toluene or methyl cellosolve (ethylene glycol monomethyl ether), but preferably in methanol It is advantageous if the reaction medium is as far as 5 possible anhydrous.
The reaction is carried out at a temperature between O and 70 C, preferably between 30 and 50 C, and in the presence of a base Especially suitable bases are amines, preferably primary amines and ammonia.
A particularly advantageous embodiment of the synthesis of the compounds of 10 the formula I comprises reacting the acetoacetic amide of the formula III (obtained in the preliminary step by reacting the aminonitrile with the diketene as starting material) in situ with the benzofuroxane of the formula II to give the desired compound of the formula I.
A further method of obtaining the compounds of the formula I is the following 15 synthesis known per se from British Patent Specification 1,308,370:
+ %CH 3 CO-CH 2 COOR’ > (II) QO i R N OOR’ + HN-A-CN AI D -.N’ H 3 (Ia) O 0 R CO -N A-CN (I) N CH 3 wherein R’ represents an alkyl group of 1 to 4 carbon atoms 20 The starting materials of the formula III for obtaining the compounds of the present invention of the formula I are partly novel and partly known They can be obtained by methods which are known per see from amines and diketenes (cf.
Houben-Weyl 7/4, page 234 and 8, page 658).
RR R CH 2 R H-N-A CN + CH 3 CO-CH 2 CO-N-A-CN 25 0 (III) 1 50034 3 1,569,034 3 The manufacture of the starting compounds is carried out at temperatures between -15 and + 300 C, preferably between -10 and O C The reaction takes place in an inert organic solvent Especially suitable solvents are alcohols, such as ethanol or isopropanol, preferably methanol It is advantageous to carry out the reaction in anhydrous medium.
The following synthesis is commonly known as a further method of manufacture:
R CH 3 COCH 2 COOR’ +IHN-A-CN > R CH 3 COCH 2 CO-N-A-CN (II I) The manufacture of the benzofuroxane of the formula II is described in “Organic Syntheses”, page 74 10 Compounds similar to the compounds of the present invention of the formula I are already known from DOS 1,670,935, DOS 1,620,114, and from British Patent Specification 1,223,720 The compounds of this invention of the formula I are far superior to the known compounds for controlling pathogenic microorganisms and, compared with them are characterised in particular by a more pronounced 15 therapeutic action.
The compounds of the formula I have a good microbicidal action and are suitable chiefly for controlling pathogenic microorganisms in the sphere of veterinary medicine They are characterised especially by an excellent action against diseases of the respiratory tract in poultry caused by E coli 20 Furthermore, the compounds of the formula I of the present invention can be used to combat infections of the intestinal tract, for example swine diarrhoea, and of the urogenital system In addition, they possess good growthstimulating properties in non-human animals and productive livestock, such as swine, poultry, and ruminants 25 The following compounds are to be singled out for their special activity in respect of their biological properties:
1,4-dioxido-3-methyl-quinoxaline( 2)-N-( 2 ‘-cyanoethyl)-carboxamide, 1,4-dioxido-3-methyl-quinoxaline( 2)-N-(cyanomethyl)-carboxamide, 1,4-dioxido-3-methyl-quinoxaline( 2)-N-( 1 ‘-cyanoisopropyl)-carboxamide, 30 1,4-dioxido-3-methyl-quinoxaline( 2)-N-( 3 ‘cyanopropyl)-carboxamide, 1,4-dioxido-3-methyl-quinoxaline( 2)-N-( 4 ‘cyanobutyl)-carboxamide.
In accordance with the use for which they are intended, the active compounds of the invention can be administered as pure active substance or combined with an inert carrier diluent, and/or dispersant to non-human animals They can be 35 administered direct perorally, abomasally or by injection, in the form of solutions, emulsions, suspensions powders, tablets, boluses and capsules, both as a single and repeated dose The active compounds and mixtures containing them can also be added to the feed or drink or they can be incorporated in feed pre-mixes All these compositions are, of course, within the scope of the invention 40 The surprisingly excellent therapeutic action of the compounds of the formula I of the present invention has been established both in vitro and especially in animals with acute bacterial infections after oral as well as subcutaneous application The activity spectrum of the compounds encompasses grampositive and gram-negative bacteria 45 As is evident from the following summary of results obtained from comparison tests with known compounds, the superiority of the compounds of the present invention can be unequivocally demonstrated.
In tests carried out on white mice, the intraperitoneally infected animals are treated subcutaneously and perorally as follows: 50 The administration is effected in doses of I mg, 3 mg, 10 mg, 30 mg, 100 mg or 300 mg of active substance per kg of body weight initially simultaneously with the infection and a second time 3 hours later.
Comparison Test 1:
ED 50 in the mouse septicaemia model ( 95 % confidence interval) Staph aureus Strept pyog Bacteria Smith Aronson E coli 205 Salm ty -m Past mult Pseud aerug.
Compounds average effective dose/confidence interval in mg of active substance/kg of body weight 2 x sc 10 ( 7 14) 205 (ED 20) 3 ( 2 2 4 2) 3 9 ( 2 6 5 7) 3 0 ( 2 1 -4 2) 120 ( 66 218) A 2 x po 12 ( 10 15) 265 ( 162 433) 3 5 ( 2 5 5 0) 4 2 ( 2 9 5 7) 3 4 ( 2 4 4 7) 75 ( 48 116) 2 x se 16 ( 11 22) 140 (ED 20) 11 ( 8 15) 11 ( 7 7 16) 3 2 ( 2 1 4 9) > 100 B2 x po 18 ( 13 24) 170 (ED 20) 18 ( 13 24) 25 ( 17 35) 5 1 ( 3 6 -7 1) > 300 2 x sc 18 ( 13 24) 400 ( 209 762) 5 5 ( 4 1 7 4) 10 ( 6 5 15) 5 5 ( 4 0 7 6) 105 ( 59 186) c 2 x po 27 ( 19 38) 275 ( 161 468) 6 6 ( 4 8 9 1) 11 ( 7 1 17) 3 9 ( 2 8 5 4) 235 ( 146 378) 2 x sc 40 ( 29 54) 425 ( 296 -609) 9 ( 6 5 12 5) 10 ( 6 17) 14 ( 10 20) 210 ( 140 314) D 2 xpo 60 ( 46-78) 410 ( 297 -566) 10 ( 7 13) 13 ( 9 19) 15 ( 10 21) 490 ( 295 814) 2 x sc 2500 ( 1425-4375) 300 ( 210 425) 140 ( 95 207) r J 100 E 2 x po 35 ( 25 50) 30 ( 20 45) 25 ( 18 35) rv 30 2 x sc 200 ( 150 260) 150 ( 105 215) ‘,J 100 F 2 x po 280 ( 210 -370) 100 ( 70 140) c’100 sc.= subcutaneous po = peroral L^ b az o D w r 1,569,034 5 Comparative Test 2:
ED 5 o in the E coli aerosacculitis model ( 95 % confidence interval) Single peroral administration by means of a probang to simultaneously infected hens in mg of active substance per kg of body weight.
Compounds E Dso Confidence interval A 2 0 1 3 3 0 D 5 3 3 7 7 6 E 9 0 6 5 12 5 F 11 0 8 2 14 8 A = Compound 1 (of the “Compound Table” hereinafter) B = Compound 2 (of the “Compound Table” hereinafter) C Example 1
D = “Olaquindox” (DOS 1,670,935; Compound 6) E = “Carbadox” (DOS 1,620,114; Example 1) F “Grofas” (British Patent Specification 1,223,720; Compound 1,
Table on page 3; “Grofas” is a Registered Trade Mark) J Pharmacol Exper Therap 96 ( 1949), 99-113 Demonstration of growth A group of 8 piglets ( 4 d and 49) was fed for 28 days with a normal feed containing 17.6 % of raw protein and 3 4 % of crude fibres and to which 50 ppm of 1, 4-dioxido3-methyl-quinoxaline( 2)-N-( 2 ‘-cyanoethyl)-carboxamide (Example 1) had been added The average initial weight of the individual test animals was approx 9 kg at the start of the test At the conclusion of the test the animals were weighed individually and the feed consumption determined in groups For control purposes, a parallel test following the same procedure was carried out using the same feed without the addition of active substance.
1,569,034 h RESULT.
Daily growth rate 1) Feed consumption index 1) 2) Substance abs rel abs rel.
(control) 231 g 100 %C 190 100 % Compound of Example 1 305 g 132,% 1 69 88 9 % 1) Figures in average values 2) kg of feed consumed per kg of growth in weight Example 1
I,4-Dioxido-3-methvl-quinoxaline( 2)-N-( 2 ‘-cyanoethyl)-carboxamide 19.2 g of benzofuroxane are added in small amounts to a solution of 23 8 g of N-2cyanoethyl-acetoacetic amide in 80 ml of methanol and then ammonia which has 5 been dried over KOH is introduced over the course of 2 hours, while initially keeping the temperature of the solution, which has rapidly turned dark in colour, below 45 C by cooling from time to time After the formation of the heat of reaction has subsided, the temperature of the reaction mixture is kept at 40 -45 C, and, when the addition of ammonia is complete, the batch is stirred for 10 to 12 hours at the same temperature The reaction product separates out in beige-coloured crystals After cooling, the crystals are collected with suction and washed with cold methanol The resultant pure crystalline 1,4-dioxido-3methylquinoxaline( 2)-N-( 2 ‘-cyanoethyl)-carboxamide melts at 198 0-199 C It can be recrystallised from dimethyl formamide/ethanol 15 Example 2
I 4-Dioxido-3-methyl-quinoxaline( 2)-N-( 2 ‘-cyanoethyl)-carboxamide While stirring at -10 to O C, 11 8 g of freshly distilled diketene are added dropwise to a solution of 80 ml of methanol and 9 9 g of aminopropionitrile The mixture is allowed to warm to room temperature and stirred for a further 2 hours at 35 C 20 Then 19 2 g of benzofuroxane are added in small amounts to the solution of N-2cyanoethylacetoacetic amide and thereafter ammonia which has been dried over KOH is introduced over the course of 8 hours, while keeping the temperature of the solution, which has rapidly turned dark in colour, below 45 C by cooling from time to time After the formation of the heat of reaction has subsided the 25 temperature of the reaction mixture is kept at 40 -45 C, and, when the addition of ammonia is complete the batch is stirred for 10 to 12 hours at the same temperature The reaction product separates out in the form of beigecoloured crystals After cooling, the crystals are collected with suction and washed with cold methanol The resultant pure 1,4-dioxido-3-methyl-quinoxaline-( 2)-N-( 2 ‘ 30 cyanoethyl)-carboxamide melts at 198 -199 C It can be recrystallised from dimethyl formamide/ethanol.
Example 3
Acetoacetic N-c’anomethy’lamnide While stiring at -10 to O C, 92 g of freshly distilled diketene are added dropwise to 35 a solution of 400 ml of methanol and 56 g of freshly distilled aminoacetonitrile The mixture is allowed to warm to room temperature and stirring is continued for 2 hours at 35 C in a water bath The solvent is distilled off by rotary evaporation and the solid residue is suspended in cold ether Suction filtration yields the colourless, crystalline, pure acetoacetic N-cyanomethylamide with a melting point of 40 63 -65 C.
The following compounds were obtained by a process analogous to that described in Examples I and 2:
1,569,034 7 1,569,034 7 COMPOUND TABLE 0 R N co-N l I C N A-CH (I) Example 4
Feed additives Example 4 The following feed mixes were prepared to obtain individual amounts of 6000 parts by weight of end feed containing a) 25 ppm b) 50 ppm c) 200 ppm and c) 400 ppm: 5 a) 0 15 part by weight of one of the compounds of the formula I 49.85 parts by weight of Bolus alba 0 parts by weight of standard feed for poultry, swine or ruminants.
b) 0 30 part by weight of one of the compounds of formula I 44.70 parts by weight of Bolus alba 10 5.0 parts by weight of silicic acid 0 parts by weight of standard feed for poultry, swine or ruminants.
c) 1 2 parts by weight of one of the compounds of the formula I 43 8 parts by weight of Bolus alba 5.0 parts by weight of silicic acid 15 0 parts by weight of standard feed for poultry, swine and ruminants.
d) 2 4 parts by weight of one of the compounds of formula I 47.6 parts by weight of Bolus alba 150 0 parts by weight of standard feed for poultry, swine or ruminants, The active substances are mixed with the carrier materials either direct or 20 applied thereto dissolved in chloroform, and the mixtures are subseqaently ground to the desired particle size of, for example, 5 to 10 a The feed premixes are mixed with 5800 parts by weight of standard feed or processed to 6000 parts by weight of ready-for-use beverages In addition, the end feed mixes can be processed to pellets (feed pellets) 25 The active compounds of the formula I are added to the feed or beverages for the animals in amounts of I to 500 ppm, referred to the total feed or beverage, either direct or in the form of a premix.
Suitable premixes consist for example of a mixture of the active compound with kaolin, chalk, alumina, ground mussel shells, Bolus alba, “Aerosil” 30 (Registered Trade Mark), starch or lactose A feed mix is prepared by thoroughly mixing the required amount of premix with the corresponding amount of a standard commercial feed.

Claims (1)

WHAT WE CLAIM IS: 35
1 Quinoxaline-di-N-oxide derivatives of the formula I 0 o R CO N/ A-CN (I) N CH 3 o 0 wherein R represents a hydrogen atom, an alkyl group or I to 12 carbon atoms, a cyanoalkyl group containing I to 4 carbon atoms in the alkyl portion thereof or 40 an allyl group, and A represents a straight-chain or branched alkylene bridge member containing 1 to 4 carbon atoms.
2 1,4-Dioxido-3-methyl-quinoxaline( 2)-N-( 2 ‘-cyanoethyl)-carboxamide.
3 1,4-Dioxido-3-methyl-quinoxaline( 2)-N-(cyanomethyl)-carboxamide 45 4 1,4-Dioxido-3-methyl-quinoxaline( 2)-N-( 1 ‘-cyanoisopropyl)carboxamide.
1,4-Dioxido-3-methyl-quinoxaline( 2)-N-( 3 ‘-cyanopropyl)-carboxamide.
6 1,4-Dioxido-3-methyl-quinoxaline( 2)-N-( 4 ‘-cyanobutyl)-carboxamide.
7 A process for the manufacture of a compound of the formula I according to claim 1, which comprises reacting the compound of the formula II 50 1.569034 f S o (II) with a compound of the formula 111 R CH 3 CH-CH 2 CO-N-A-CN ( 111) in which R and A are as defined in formula 1, in an inert organic solvent in the presence of a base, at a temperature between O and 70 TC 5 8 A process for the manufacture of a compound of the formula I according to claim 1, which comprises reacting a compound of the formula R H-N-A-CN in which R and A are as defined in formula 1, with the diketene of the formula CH 2 0 1 in an inert organic solvent at a temperature between -15 and + 300 C to give a compound of the formula 111 R CH 3 CO-CH 2 CO-N-A-CN () in which R and A are as defined in formula I, and, immediately thereafter, reacting the compound of the formula (III), without isolating it, with the benzofuroxane of 15 the formula II in the presence of a base at a temperature between 00 and 70 TC.
9 A composition for controlling harmful microorganisms in a non-human animal, with contains as active component at least one compound of the formula I 20 according to claim 1, together with an inert carrier diluent and/or dispersant.
A composition for combating diseases of the respiratory tract in poultry caused by E coli, which contains as active component at least one compound of the formula I according to claim 1, together with an inert carrier, diluent and/or dispersant 25 11 A composition for stimulating the growth of non-human domestic animals and productive livestock, which contains as active component at least one compound of the formula I according to claim 1, together with an inert carrier diluent and/or dispersant.
12 A method of controlling harmful microorganisms, in a non-human animal, 30 which comprises administering to the animal a compound of the formula I according to claim 1.
13 A method of combating diseases of the respiratory tract in poultry caused by E coli, which comprises administering to the poultry a compound of the -; formula I according to claim 1 _ 1,569,034 1,569,034 10 14 A method of promoting the growth of non-human domestic animals and productive livestock, which comprises administering, to the animal a compound of the formula I according to claim 1.
J A KEMP & CO, Chartered Patent Agents, 14, South Square, Gray’s Inn, London,WC 1 R 5 EU.
Printed for Her Majesty’s Stationery Office by the Courier Press, Leamington Spa, 1980.
Published by the Patent Office, 25 Southampton Buildings, London, WC 2 A l AY, from which copies may be obtained.

GB2356/77A
1976-01-20
1977-01-20
1,4-dioxido-3-methyl-quinoxaline (2) carboxamides

Expired

GB1569034A
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

CH63476A

CH627174A5
(en)

1976-01-20
1976-01-20
Process for the preparation of quinoxaline di-N-oxide derivatives

CH1492076

1976-11-26

Publications (1)

Publication Number
Publication Date

GB1569034A
true

GB1569034A
(en)

1980-06-11

Family
ID=25685198
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

GB2356/77A
Expired

GB1569034A
(en)

1976-01-20
1977-01-20
1,4-dioxido-3-methyl-quinoxaline (2) carboxamides

Country Status (21)

Country
Link

US
(1)

US4092415A
(en)

JP
(1)

JPS5289683A
(en)

AU
(1)

AU515192B2
(en)

BR
(1)

BR7700355A
(en)

CA
(1)

CA1108143A
(en)

DE
(1)

DE2701707C2
(en)

DK
(1)

DK141509B
(en)

EG
(1)

EG13191A
(en)

ES
(1)

ES455158A1
(en)

FR
(1)

FR2338935A1
(en)

GB
(1)

GB1569034A
(en)

HK
(1)

HK41283A
(en)

IL
(1)

IL51292A
(en)

KE
(1)

KE3289A
(en)

MY
(1)

MY8400251A
(en)

NL
(1)

NL7700581A
(en)

NZ
(1)

NZ183118A
(en)

SE
(1)

SE427928B
(en)

SG
(1)

SG28883G
(en)

SU
(1)

SU890961A3
(en)

YU
(2)

YU39221B
(en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

IT7869686D0
(en)

1978-11-24
1978-11-24
Loranze Torino A

PROCEDURE FOR PREPARATION OF 2METHYL 3 BIDROXYETHYL CARBAMOLLCHINOXALINE I.4 OF PURE N OXIDE AND OTHER COMPOUNDS SIMILAR TO IT

US4254120A
(en)

1978-12-19
1981-03-03
Ciba-Geigy Corporation
Growth promoting quinoxaline-di-N-oxide carboxamides

US4418063A
(en)

1978-12-19
1983-11-29
Ciba-Geigy Corporation
Growth promoting quinoxaline-di-N-oxide carboxamides

DE3133888A1
(en)

1981-08-27
1983-03-10
Bayer Ag

ACTIVE COMBINATION OF KITASAMYCIN AND CHINOXALIN-DI-N-OXIDES

JPH06701B2
(en)

1983-12-01
1994-01-05
旭化成工業株式会社

Veterinary composition

ES2707876T3
(en)

2010-12-20
2019-04-05
Dsm Ip Assets Bv

Use of organic nitrooxy molecules in feed to reduce methane emission in ruminants

EP2644038A1
(en)

2012-03-26
2013-10-02
DSM IP Assets B.V.
Use of para nitro amino derivatives in feed for reducing meth-ane emission in ruminants

Family Cites Families (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

DE1670935C3
(en)

1967-10-04
1975-12-04
Bayer Ag, 5090 Leverkusen

2-Methyl-3-carboxamidoquinoxaline-1,4-dl-N-oxides, a process for their preparation and antibacterial agents containing these compounds

GB1223720A
(en)

1968-10-30
1971-03-03
Ici Ltd
Growth promotion

US3635972A
(en)

1969-07-22
1972-01-18
Pfizer
3-methyl-2-quinoxalinecarboxamidedi-n-oxides

1977

1977-01-10
SU
SU772437355A
patent/SU890961A3/en
active

1977-01-13
US
US05/758,973
patent/US4092415A/en
not_active
Expired – Lifetime

1977-01-17
EG
EG33/77A
patent/EG13191A/en
active

1977-01-17
DE
DE2701707A
patent/DE2701707C2/en
not_active
Expired

1977-01-18
CA
CA269,894A
patent/CA1108143A/en
not_active
Expired

1977-01-19
SE
SE7700529A
patent/SE427928B/en
not_active
IP Right Cessation

1977-01-19
YU
YU00135/77A
patent/YU39221B/en
unknown

1977-01-19
BR
BR7700355A
patent/BR7700355A/en
unknown

1977-01-19
AU
AU21443/77A
patent/AU515192B2/en
not_active
Ceased

1977-01-19
ES
ES455158A
patent/ES455158A1/en
not_active
Expired

1977-01-19
DK
DK20277AA
patent/DK141509B/en
not_active
IP Right Cessation

1977-01-19
NZ
NZ183118A
patent/NZ183118A/en
unknown

1977-01-19
IL
IL51292A
patent/IL51292A/en
unknown

1977-01-19
FR
FR7701398A
patent/FR2338935A1/en
active
Granted

1977-01-20
NL
NL7700581A
patent/NL7700581A/en
not_active
Application Discontinuation

1977-01-20
JP
JP539577A
patent/JPS5289683A/en
active
Granted

1977-01-20
GB
GB2356/77A
patent/GB1569034A/en
not_active
Expired

1982

1982-07-13
YU
YU1534/82A
patent/YU40081B/en
unknown

1983

1983-05-20
KE
KE3289A
patent/KE3289A/en
unknown

1983-05-24
SG
SG288/83A
patent/SG28883G/en
unknown

1983-10-13
HK
HK412/83A
patent/HK41283A/en
unknown

1984

1984-12-30
MY
MY251/84A
patent/MY8400251A/en
unknown

Also Published As

Publication number
Publication date

AU515192B2
(en)

1981-03-19

IL51292A0
(en)

1977-03-31

YU13577A
(en)

1982-10-31

BR7700355A
(en)

1977-09-20

KE3289A
(en)

1983-06-17

DE2701707A1
(en)

1977-07-21

US4092415A
(en)

1978-05-30

YU39221B
(en)

1984-08-31

JPS6135985B2
(en)

1986-08-15

HK41283A
(en)

1983-10-21

NZ183118A
(en)

1979-12-11

MY8400251A
(en)

1984-12-31

JPS5289683A
(en)

1977-07-27

SE427928B
(en)

1983-05-24

YU153482A
(en)

1982-10-31

SG28883G
(en)

1984-04-19

DE2701707C2
(en)

1986-05-22

IL51292A
(en)

1981-06-29

AU2144377A
(en)

1978-07-27

SE7700529L
(en)

1977-07-21

CA1108143A
(en)

1981-09-01

DK141509C
(en)

1980-09-29

FR2338935B1
(en)

1979-03-23

NL7700581A
(en)

1977-07-22

FR2338935A1
(en)

1977-08-19

DK20277A
(en)

1977-07-21

YU40081B
(en)

1985-06-30

DK141509B
(en)

1980-04-08

ES455158A1
(en)

1978-04-01

SU890961A3
(en)

1981-12-15

EG13191A
(en)

1980-12-31

Contact information